All of us at $LCTX and CCN wish to express our gratitude to those who inspire us as #WeWorktoRestore - function, dignity, strength, clarity, independence, and hope. @CEO_Culley #CellTherapy #ReplaceAndRestore #Careers

Join us on September 29 for the @scipfdd Spinal Cord Injury Patient-Focused Drug Development Meeting — a free, virtual event where the SCI community will share their experiences and needs directly with the FDA. Register: scipfdd.org/register @CEO_Culley #SCIPFDD #SCI #PFDD @reevefoundation @CIRMnews @U2FP_CureSCI @ASIA_spine @PVA1946 @NASCIC1 @UnitedSpinal @SCoBIRC

Register now for the free, virtual @scipfdd SCI PFDD Meeting on Sept. 29! Participants will discuss daily life with SCI, experiences with treatments, and priorities for future research. Register: scipfdd.org/register @CEO_Culley #SCIPFDD #SCI #PFDD @reevefoundation @CIRMnews @U2FP_CureSCI @ASIA_spine @PVA1946 @NASCIC1 @UnitedSpinal @SCoBIRC

Lineage is proud to support the upcoming @scipfdd SCI Patient-Focused Drug Development (PFDD) Meeting on September 29! This free, virtual event brings the experiences of individuals with SCI directly to FDA and treatment developers. scipfdd.org/register @CEO_Culley #SCIPFDD #SCI #PFDD @reevefoundation @CIRMnews @U2FP_CureSCI @ASIA_spine @PVA1946 @NASCIC1 @UnitedSpinal @SCoBIRC

Today, $LCTX announced the issuance of a U.S. Patent covering the company’s proprietary AlloSCOPE™ 5D manufacturing platform. investor.lineagecell.com/new… #CellManufacturing #ReplaceAndRestore

On #WorldSCIDay, all of us at $LCTX would like to recognize decades of collective global effort to raise awareness, strengthen prevention, and advance meaningful action for people living with spinal cord injury. Learn more about World SCI Day: iscos.org.uk/page/SciDay @CEO_Culley | @ISCoSmeetings #CellTherapy #SCI

$LCTX reported second quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update. Learn more: bit.ly/4xtq2io @CEO_Culley | #ReplaceAndRestore

$LCTX announced it will report Q2 2026 financial and operating results on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update. For more: bit.ly/4w0R3IP #ReplaceAndRestore

$LCTX thanks @DDWJournal for featuring @CEO_Culley in its Summer 2026 issue. Brian discusses the potential of cell replacement therapies in ophthalmology, including Lineage’s recently launched and wholly owned COR1 program, and the AlloSCOPE™ platform. bit.ly/4pwHPT7

$LCTX wishes to thank @Eyecelerator and distinguished moderators @allenho and SriniVas Sadda, MD, FARVO, for including the OpRegen® cell therapy program in the panel “Is Vision Improvement on the Horizon for Regenerative Medicine?” at Eyecelerator @ ARVO 2026. Watch the full panel: bit.ly/4vAgTD7 @CEO_Culley | @GenentechEye | #CellTherapy #RegenerativeMedicine #Ophthalmology #DryAMD

$LCTX will discuss progress with its COR1 preclinical program for corneal endothelial disease during a conference call today at 4:30 p.m. ET / 1:30 p.m. PT. For more: bit.ly/4vv3qwC #Ophthalmology #ReplaceandRestore

$LCTX @CEO_Culley will participate in a fireside chat hosted by Mayank Mamtani of B. Riley Securities as part of the 2026 Mind, Muscle & Vision Healthcare Summit on July 16 in Boston. For more: bit.ly/3R45Xzo #CellTherapy #Biotech #RegenerativeMedicine #ReplaceandRestore

Jill Howe, CFO of $LCTX, joined CFO Weekly to discuss how biotech finance teams can build systems that create bandwidth for the organization. In the episode, Jill shares her perspective on streamlining procurement and clinical operations, building lean AP workflows, and approaching AI as a practical tool for the finance function. Apple Podcasts: apple.co/4aorBoK YouTube: bit.ly/4vxaUQw @Personiv | #CFOLeadership #FinanceFunction

Thank you to @RetinalPhys and authors @eyeballsurgeon and Ben Uzorka for including OpRegen® in their review of the therapeutic pipeline for geographic atrophy (GA). Read the full article: bit.ly/3QYhIra #GeographicAtrophy #DryAMD #CellTherapy

Thank you to @CTS_Tahoe and @ArshadKhanani for hosting $LCTX @CEO_Culley as part of the “From Innovation to Approval: Bringing Novel Treatments to Market” panel at Clinical Trials at the Summit 2026. #CTS2026 #CTSRetina #Ophthalmology

$LCTX @CEO_Culley will present on the “From Innovation to Approval: Bringing Novel Treatments to Market” panel at Clinical Trials at the Summit (@CTS_Tahoe) 2026. The session will be moderated by Pravin U. Dugel, M.D., of @OCUTX and will include executive presenters from @AbbVie, Oculis, Valitor Bio, @NeurotechPharma, RecensMedical, and others. Learn more: bit.ly/446UTEp @ArshadKhanani | #CTS2026 #CTSRetina #ClinicalTrials #Ophthalmology

We appreciate Dr. Joe Pantginis of @HCWCO for hosting a fireside chat with $LCTX ‘s @CEO_Culley as part of @HCWCO 4th Annual BioConnect Investor Conference at @NasdaqExchange. Replay available here: bit.ly/3m7EWIp #CellTherapy #InvestorRelations #ReplaceandRestore

We’d like to thank European Pharmaceutical Review for featuring $LCTX ’s @CEO_Culley in its 2026 Cell and Gene Therapy report, where he discusses scalable, off-the-shelf cell therapies and the role of manufacturing, scale, and control in development. Read the full report: bit.ly/4eMqL8i #CellTherapy #RegenerativeMedicine #CellManufacturing

$LCTX reported first quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update. Learn more: bit.ly/4nn1p2W #ReplaceAndRestore

$LCTX will report Q1 2026 financial and operating results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update. For more: investor.lineagecell.com/new… #ReplaceAndRestore

OpRegen® (RG6501) 3-year Phase 1/2a clinical study results in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented at @FightBlindness’ Retinal Therapeutics Innovation Summit 2026 on behalf of @Roche and @Genentech. Imaging evidence of structural benefit and greater gains in visual acuity seen in study eyes in Cohort 4 patients (less advanced GA) at month 12, continuing through month 36. Differences as compared with fellow eyes increased over time, suggesting possible modification of the course of disease. For more: bit.ly/497P4K4 $LCTX #CellTherapy #GeographicAtrophy #AMD #Retina